ARTIVION, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Artivion Inc. (AORT) reported Q2 2026 revenue growth of 11% to $125.8M, driven by its aortic arch portfolio. However, it posted a net loss of $13.5M, reversing from a profit a year earlier. The company completed the Endospan acquisition and received FDA approval for AMDS. Despite growth, profitability declined, and guidance was reiterated without an increase.
GREEN ANDREW M (SVP, Regulatory and Quality) sold 11,480 shares of ARTIVION, INC. (AORT) at $24.97 ($0.29M total) on 2026-09-10.
GREEN ANDREW M (SVP, Regulatory and Quality) sold 8,003 shares of ARTIVION, INC. (AORT) at an average of $27.03 ($26.02–$27.26, $0.22M total) across 2 trades over 2026-09-02 to 2026-09-03.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AORT (ARTIVION, INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent AORT coverage spans earnings, insider activity and market movers.
In the last 30 days, AORT insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($2.5M). The most active reporter was GREEN ANDREW M, SVP, Regulatory and Quality, with 3 filings.
The earnings miss and widening loss likely pressure the stock, while revenue growth and FDA approval provide upside catalysts.
Insider sale may signal lack of confidence or portfolio rebalancing, potentially pressuring the stock short-term.
Insider sale of modest size may signal limited confidence but impact on price is likely minimal.
Insider sale by the CEO may signal reduced confidence, potentially pressuring the stock lower.
Earnings miss may pressure the stock short-term; however, FDA approval for AMDS could support upside if margins improve.
AlphAI scores every news story that mentions AORT with an AI model for sentiment and relevance, and aggregates insider trades from ARTIVION, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Artivion Inc. (AORT) reported Q2 2026 revenue growth of 11% to $125.8M, driven by its aortic arch portfolio. However, it posted a net loss of $13.5M, reversing from a profit a year earlier. The company completed the Endospan acquisition and received FDA approval for AMDS. Despite growth, profitability declined, and guidance was reiterated without an increase.
3 min readGREEN ANDREW M (SVP, Regulatory and Quality) sold 11,480 shares of ARTIVION, INC. (AORT) at $24.97 ($0.29M total) on 2026-09-10.
1 min readGREEN ANDREW M (SVP, Regulatory and Quality) sold 8,003 shares of ARTIVION, INC. (AORT) at an average of $27.03 ($26.02–$27.26, $0.22M total) across 2 trades over 2026-09-02 to 2026-09-03.
1 min readMackin James P (President & CEO) sold 70,000 shares of ARTIVION, INC. (AORT) at $28.96 ($2.03M total) on 2026-08-19.
1 min readArtivion (AORT) reported Q2 2026 revenue of $125.76M, up from $112.97M a year earlier, but shifted from net income to a loss of $13.51M. H1 2026 revenue rose to $242.09M, but the company moved to a net loss of $12.09M. The company projects $619.8M revenue and $44.7M earnings by 2029, requiring 10.6% yearly revenue growth.
3 min readArtivion (AORT) shares rose 2.5% after Canaccord Genuity raised its price target to $40, citing strong Q2 revenue of $125.8M. The stock later cooled to $29.57, up 2.3%. The company's shares have been volatile, with a 26.8% drop in May after missing earnings estimates and lowering guidance. AORT is down 33.5% YTD.
2 min readArtivion (AORT) reported Q2 2026 revenue of $125.8M, up 9% constant currency, and adjusted EBITDA of $26.4M. The company completed the Endospan acquisition and received late-June FDA PMA approval for AMDS, expecting faster account conversion. Full-year guidance was reiterated at $480M to $496M revenue and $92M to $99M adjusted EBITDA; FCF was negative $12M.
7 min readArtivion’s Q2 update highlights 12% YoY growth in stent graft revenues and 18% growth in its On-X mechanical heart valve portfolio. The company says its NEXUS Aortic Arch Stent Graft acquisition (Endospan) completed and that AMDS received full FDA approval, supporting adoption. Management expects near-term margin and cash flow pressure from R&D and integration.
6 min readArtivion, Inc. (AORT) reported Q2 revenue of $125.8 million and a net loss of $13.5 million, or 28 cents per share, versus a profit a year earlier. Adjusted earnings were 13 cents per share. The company expects full-year revenue of $480 million to $496 million. Shares fell sharply year to date.
3 min readArtivion (NYSE:AORT) reported Q2 CY2026 revenue of $125.8 million, up 11.3% year over year and 4.4% above Wall Street estimates, according to the company. Non-GAAP EPS was $0.13, clearing consensus. The company guided full-year revenue to about $488 million and expects EPS around $0.54.
4 min read
